Uncovering Advantages of the Typhoid Vaccine
The first conjugate vaccine for typhoid—Bharat Biotech’s Typbar-TCV®—offers significant advantages over previous vaccines, including the need for fewer doses and its use in children under the age of 2, says Kathleen M. Neuzil, director, Center for Vaccine Development at the University of Maryland School of Medicine.
In an exclusive Q&A with GHN, Neuzil explains the advantages, where the vaccine will be available first and an update on the latest impact studies.
- “The incorporation of Typbar-TCV into routine vaccination schedules is the best way to reach children most at risk for typhoid.”
- “Gavi, the Vaccine Alliance, recently approved US $85 million to support the introduction of typhoid conjugate vaccines, including Typbar-TCV.”
- “Typbar-TCV is licensed for private use in India and Nepal and registered in Nigeria and Cambodia with 30 additional registrations in progress.”